Abstract
To determine the optimal dose(s) of once-monthly administration of efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA), in patients with type 2 diabetes (T2D) inadequately controlled on metformin. In this phase 2, randomized, placebo-controlled, double-blind trial (NCT02081118), patients were randomized 1:1:1:1 to subcutaneous efpeglenatide (8, 12 or 16 mg once monthly; n = 158) or placebo (n = 51). The 16-week treatment period included a 4-week titration phase with once-weekly efpeglenatide 4 mg, followed by one dose of efpeglenatide 8 mg once monthly and two doses of the assigned once-monthly dose. The primary endpoint was change in glycated haemoglobin (HbA1c) from baseline to week 17. All efpeglenatide doses significantly reduced HbA1c versus placebo (P < 0.0001 for all). Overall, the least squares mean difference in HbA1c reductions between efpeglenatide and placebo was -7.7 mmol/mol (-0.71%; baseline to week 17). At week 17, a significantly greater proportion of efpeglenatide patients had an HbA1c level <53 mmol/mol (<7%) versus placebo (48.7% vs. 30.6%; P = 0.0320). Significant body weight loss occurred across all efpeglenatide doses (placebo-corrected reduction -2.0 kg [efpeglenatide overall]...Continue Reading
References
Sep 3, 2004·Diabetes/metabolism Research and Reviews·Mark S FinemanAlain D Baron
Jun 7, 2008·The Diabetes Educator·Mary E LarkinDavid M Nathan
Jul 14, 2009·Diabetes Care·Julio RosenstockUNKNOWN Albiglutide Study Group
Nov 20, 2009·Current Medical Research and Opinion·Catherine E CookeStuart T Haines
May 6, 2011·Diabetes Care·Alan J Garber
Feb 9, 2012·Diabetic Medicine : a Journal of the British Diabetic Association·M PeyrotP-M Schumm-Draeger
Jun 26, 2012·Diabetes, Obesity & Metabolism·M PeyrotP-M Schumm-Draeger
Jul 19, 2012·Diabetic Medicine : a Journal of the British Diabetic Association·G GrunbergerZ Milicevic
Aug 31, 2013·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Luis-Emilio García-PérezDomingo Orozco-Beltrán
Sep 6, 2014·The Lancet. Diabetes & Endocrinology·Stephen C L GoughUNKNOWN NN9068-3697 (DUAL-I) trial investigators
Oct 23, 2015·Diabetes, Obesity & Metabolism·Michael Nauck
Nov 10, 2015·Current Medical Research and Opinion·A Brett HauberJames Ruggles
Dec 5, 2015·Patient Preference and Adherence·Heather L GelhornKristina S Boye
Dec 24, 2015·Current Diabetes Reviews·Scott R Drab
Jun 18, 2016·Diabetes Care·Michael NauckBertrand Cariou
Jul 16, 2016·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Qing QiaoKarel Kostev
Jul 21, 2016·Diabetes Care·Carol H WyshamElise Hardy
Aug 16, 2016·Patient Preference and Adherence·William H Polonsky, Robert R Henry
Aug 17, 2016·Diabetes Care·Julio RosenstockUNKNOWN LixiLan-O Trial Investigators
Oct 22, 2016·Frontiers in Immunology·Ji-Hee HaYong-Sung Kim
Feb 6, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Lei QinSusan Grandy
Feb 27, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Lei QinSusan Grandy
Aug 13, 2017·Diabetes Care·Steven V Edelman, William H Polonsky
Aug 13, 2017·Diabetes Care·Ginger S CarlsWilliam H Polonsky
Oct 7, 2018·Diabetes Care·Melanie J DaviesJohn B Buse
Sep 10, 2019·European Heart Journal·Francesco CosentinoUNKNOWN ESC Scientific Document Group
Citations
Jul 11, 2020·Expert Opinion on Drug Discovery·Karl Sebastian JohanssonMikkel Bring Christensen
Mar 17, 2020·Diabetes, Obesity & Metabolism·Kun-Ho YoonChristopher H Sorli
Oct 8, 2020·Diabetes, Obesity & Metabolism·Hertzel C GersteinNaveed Sattar
Mar 9, 2021·Endocrinology and Metabolism·Hun Jee Choe, Young Min Cho
Jun 27, 2021·BMJ Open Diabetes Research & Care·Marcus HompeschLinda Morrow
Jul 8, 2021·Expert Review of Clinical Pharmacology·Dhiren Patel, April Smith